The intent of this website, developed by Roche New Zealand, is to support and improve outcomes for patients prescribed HEMLIBRA for the treatment of haemophilia A with and without inhibitors.

This website is as an educational resource to help you and your whanau learn more about what to expect from treatment with HEMLIBRA. It does not take the place of individual advice from your healthcare professional.

More information about HEMLIBRA is available in the Consumer Medicines Information at medsafe.govt.nz

HEMLIBRA is a treatment for people of all ages with haemophilia A with or without factor VIII inhibitors

 

About HEMLIBRA

what is hemlibra

What is HEMLIBRA

Find out about HEMLIBRA – a prescription medicine that can help prevent or reduce the frequency of bleeding episodes in people with haemophilia A, with or without factor VIII inhibitors.

Taking Hemlibra

Taking HEMLIBRA

HEMLIBRA is given either once a week, every two weeks or every four weeks by injection under the skin (subcutaneously). Find out what you need to know about taking HEMLIBRA.

Dosing

Dosing

Find out more about the recommended dose of HEMLIBRA.

Storage

Storage

Learn how to correctly store your HEMLIBRA medication and safely dispose of needles and syringes.

Safety Information

HEMLIBRA has risks and benefits. As with all medications, there are several side effects that are associated with taking HEMLIBRA. Before you start treatment with HEMLIBRA, it is important that you are aware of all potential side effects of the medication. Always contact your healthcare provider immediately if you have any concerns regarding side effects.

HEMLIBRA® Consumer Panel

HEMLIBRA®(emicizumab), 30 mg in 1 mL, 60 mg in 0.4 mL, 105 mg in 0.7 mL and 150 mg in 1 mL ready-to-use solution for subcutaneous (SC) injection, is a Prescription Medicine used to prevent bleeding or reduce the frequency of bleeding in people with haemophilia A with or without factor VIII inhibitors.

Ask your doctor if HEMLIBRA® is right for you.

HEMLIBRA is funded for patients with haemophilia A with inhibitors, who meet predefined criteria. From 1 October 2023 HEMLIBRA is also funded for people with haemophilia A, without inhibitors, who meet predefined criteria.

Use only as directed. If symptoms continue or you have side effects, see your healthcare professional. For more information about HEMLIBRA®:

HEMLIBRA® has risks and benefits.

Possible common side effects include: injection site reactions, headache, joint pains, high temperature or fever, diarrhoea, muscle aches, hives (urticaria), rash; swollen lips, mouth, face, tongue and/or throat and/or difficulty in swallowing and breathing (angioedema).

Do not use HEMLIBRA® if: you have had an allergic reaction to HEMLIBRA or any of the ingredients, or to any medicines that are made using Chinese hamster ovary cells.

Tell your doctor if: you have allergies to any other medicines, foods, preservatives or dyes; you are taking bypassing agents or any other blood product; you are pregnant or plan to become pregnant or are breastfeeding; you are using any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Tell your doctor immediately or go to your nearest Accident and Emergency Centre if you notice any of the following: confusion, weakness, swelling of arms and legs, yellowing of skin and eyes, abdominal or back pain, feeling sick (nausea), being sick (vomiting) or urinating less – may be signs of thrombotic microangiopathy (TMA); swelling, warmth, pain or redness – may be signs of a blood clot in a vein near the surface of the skin; headache, numbness in your face, eye pain or swelling or vision impairment – may be signs of a blood clot in a vein behind your eye; blackening of the skin – may be a sign of severe damage to the skin tissue; if it appears that HEMLIBRA is no longer working for you – an uncommon occurrence of antibody production against HEMLIBRA.

Panel dated 10 July 2023. All trademarks mentioned herein are protected by law. Roche Products (New Zealand) Limited, Auckland.

M-NZ-00000217v4/MR9586/AUG2023 This site was last updated in AUG 2023

Access to this site is subject to the terms in our Legal Statement & Privacy Statement; you accept these terms by continuing to access this site.

© 2023 Roche Products (New Zealand) Ltd.

Link to Third Party Site

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet. Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Click OK to continue.

Cancel OK